Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: alcon  medical  pharmaceuticals  lifestyle  cataract  surgery  treatment  sight  multivu  8068751  livanova  medical  technology  therapy  health  treatment  drug  vns  epilepsy  multivu  7966451  health  pain  treatment  knee  chronic  life  hip  osteoarthritis  surgery  multivu  79644241  family  health  ethicon  healthcare  surgery  treatment  cure  science  tos  multivu  7965651  health  healthcare  heart  therapy  surgery  hospital  treatment  transcatheter  medicine  multivu  7049452  ethicon  stratafix  technology  health  health  care  medical  surgery  doctor  stiches  multivu  7889651  food  drug  administration  fda  abbott  tecnis  symfony  sight  eyes  treatment  cataracts  multivu  7870151  pixeefox  spiderweb  facelift  plasticsurgery  nonsurgical  procedure  face  lift  istanbul  bulentcihantimur  brain  health  neurological  psychology  neuropsychology  university  pittsburgh  brookdale  multivu  7722157  pet  dog  cute  opening  purina  family  hospital  health  children  multivu  7835951  immortality  neurosurgery  justice  legal  ethics  politics  the  immortal  joseph  walton  alfred  book  trailer  scifi  research  astro  science  cancer  early  stage  breast  cancer  health  technology  advancement  doctors  multivu  7661231 
Search // surgery
Results 1-12 of 90 for ' surgery ' (0 seconds)
A new survey from Alcon, the global leader in eye care and a division of Novartis, demonstrates that people experience significant emotional and lifestyle benefits after cataract surgery. Nearly three in four respondents who expressed an opinion agreed that after having the surgery, they were happier, more satisfied and had a greater appreciation for life. The survey also confirmed that life before surgery posed several daily challenges. A majority of survey respondents said cataracts made simple, day-to-day tasks harder, and made them feel annoyed, frustrated and old. In recognition of Cataract Awareness Month this June, Alcon conducted the MyCataracts survey with 1,300 US adults, age 60 and over, who have undergone cataract surgery, to better understand the emotional journey of the condition and the lifestyle benefits of treatment. The survey expands Alcon’s ongoing MyCataracts awareness campaign by uncovering insights that will help people make informed treatment decisions together with their doctors. To view the multimedia release go to: https://www.multivu.com/players/English/8068751-alcon-pharmaceuticals-my-cataracts-eye-care/
Categories // Miscellaneous 
Added: 175 days ago by MultiVuVideos
Runtime: 0m37s | Views: 5 | Comments: 0
Not yet rated
 

 

 

LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world. One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom. “Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.” To view the multimedia release go to: http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Categories // Miscellaneous 
Added: 378 days ago by MultiVuVideos
Runtime: 5m11s | Views: 57 | Comments: 0
Not yet rated
 

 

 

DePuy Synthes Companies today announced the launch of Hit Play, an educational initiative that encourages those dealing with hip or knee pain to stop settling for a life on ‘pause’ and instead take action to get back to the activities and people they love most. Osteoarthritis is one of the most common reasons for severe hip or knee pain, affecting nearly 27 million Americans today and will potentially affect up to 67 million people by 2030.1,2 In turn, demand for hip and knee replacements are expected to dramatically increase, yet many women see joint replacement as a “last resort” and often wait until the pain has become unbearable before turning to surgery. Through a series of compelling and relatable content, DePuy Synthes seeks to inspire the millions of people stuck on ‘pause’ due to hip or knee pain to explore joint replacement with a doctor, as a potential viable solution when they Hit Play. To view the multimedia release go to: http://www.multivu.com/players/English/79644241-lysol-madison-square-bgca-expose-germs/
Categories // Miscellaneous 
Added: 381 days ago by MultiVuVideos
Runtime: 1m13s | Views: 67 | Comments: 0
Not yet rated
 

 

 

Ethicon* joins world-renowned experts in bariatric surgery to share the latest breakthroughs in science and innovation that are advancing surgery in the fight against obesity and metabolic diseases during ObesityWeek 2016, the combined annual meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS). Ethicon will highlight the growing body of research and evidence on the benefits of bariatric surgery, a new sleeve gastrectomy training module on the Touch Surgery app, and its comprehensive portfolio of bariatric surgery products aimed to improve patient outcomes. “Ethicon’s mission is to lead the way in resolving the burden of obesity for both patients and healthcare systems by expanding access to care and demonstrating the critical value of treatment through research and evidence, while also enabling new technologies,” said Dr. Elliott Fegelman, Therapeutic Area Expert, Metabolics, Johnson & Johnson Innovation. To view the multimedia release go to: http://www.multivu.com/players/English/7965651-ethicon-bariatric-surgery-access-obesity-week-2016/
Categories // Miscellaneous 
Added: 387 days ago by MultiVuVideos
Runtime: 5m31s | Views: 136 | Comments: 0
Not yet rated
 

 

 

Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them. The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016. To view the multimedia release go to: http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
Categories // Miscellaneous 
Added: 451 days ago by MultiVuVideos
Runtime: 3m32s | Views: 119 | Comments: 0
Not yet rated
 

 

 

Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S. STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots. To view the multimedia release go to: http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
Categories // Miscellaneous 
Added: 458 days ago by MultiVuVideos
Runtime: 2m34s | Views: 133 | Comments: 0
Not yet rated
 

 

 

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony® Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfony lenses are the only lenses in the United States that provide a full range of continuous high-quality vision following cataract surgery, while also mitigating the effects of presbyopia by helping people focus on near objects. The FDA approval includes a version of the lens for people with astigmatism, the Tecnis Symfony Toric IOL. Cataracts are a common condition, with almost 4 million cataract surgeries performed each year, and that number is expected to increase.1 By age 80, more than half of all Americans either have a cataract or have had cataract surgery.2 However, cataracts do not just impact seniors. In 2016 it is estimated that nearly one in four cataract surgeries will be performed on people younger than 65.1 Many people who have cataracts experience other problems with their vision, such as presbyopia and astigmatism, which the Symfony lenses also address. Presbyopia, which affects most people over age 40, means people have lost the ability to focus on objects up close and often require glasses to perform near visual tasks. Astigmatism is when the cornea is misshapen, which causes blurry or distorted vision. To view the multimedia release go to: http://www.multivu.com/players/English/7870151-abbott-intraocular-lenses/
Categories // Miscellaneous 
Added: 496 days ago by MultiVuVideos
Runtime: 0m35s | Views: 117 | Comments: 0
Not yet rated
 

 

 

As brain health becomes an ever greater concern for people of all ages, the nation’s largest senior living provider is now guiding its residents on developing and putting into practice personalized brain health plans. Brookdale devised the new resident program with the help of a neuropsychologist specializing in brain health. The company is putting it into place at its independent and assisted living communities across the country. Through the new initiative, Brookdale’s residents will be offered a four-session course that explains key factors in brain health through classroom learning and hands-on activities. Each participant will be guided on creating an individual brain health plan to use on a daily basis. The course was developed with the assistance of Dr. Paul Nussbaum, who is Board Certified in clinical and geropsychology with a specialty in neuropsychology. An adjunct professor of neurological surgery at the University of Pittsburgh, he is the author of “Save Your Brain.” To view the multimedia release go to: http://www.multivu.com/players/English/7722157-brookdale-brain-health/
Categories // Miscellaneous 
Added: 540 days ago by MultiVuVideos
Runtime: 0m41s | Views: 131 | Comments: 0
Not yet rated
 

 

 

Madison Taliaferro spent weeks in the hospital in 2012. After a decade of suffering from cystic fibrosis, she underwent a double lung transplant. She powered through the difficult surgery and the recovery that followed –long days of physical therapy and rehabilitation. Her parents were there. Her best friend visited from Kansas. Grandparents rotated shifts so she was never alone. But one request still lingered. “I just wanted to see my dogs,” she remembers. Having suffered from the effects of chronic illness for the decade prior, Madison was no stranger to long days at home, isolated from the school germs that could turn her illness into a critical condition with a single sneeze. When her friends couldn’t visit, her dogs were there. But at the hospital, they weren’t. To view the multimedia release go to: http://www.multivu.com/players/English/7835951-purina-family-pet-center-st-louis-childrens/
Categories // Miscellaneous 
Added: 552 days ago by MultiVuVideos
Runtime: 1m20s | Views: 161 | Comments: 0
Not yet rated
 

 

 

Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated. Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal. “We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.” To view the multimedia release go to: http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Categories // Miscellaneous 
Added: 758 days ago by MultiVuVideos
Runtime: 1m25s | Views: 218 | Comments: 0
Not yet rated
 

 

 

Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated. Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal. “We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.” To view the multimedia release go to: http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Categories // Miscellaneous 
Added: 758 days ago by MultiVuVideos
Runtime: 3m4s | Views: 220 | Comments: 0
Not yet rated
 

 

 

Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated. Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal. “We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.” To view the multimedia release go to: http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Categories // Miscellaneous 
Added: 758 days ago by MultiVuVideos
Runtime: 2m3s | Views: 264 | Comments: 0
Not yet rated
 

 

 

Page 1 of 8  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2017 ClipMoon.com. All rights reserved.